Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
enVVeno Medical Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NVNO
Nasdaq
8731
https://envveno.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for enVVeno Medical Corp
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
- May 8th, 2024 8:15 pm
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
- Apr 24th, 2024 10:15 am
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
- Apr 16th, 2024 1:00 pm
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
- Apr 9th, 2024 12:45 pm
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
- Mar 15th, 2024 1:00 pm
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
- Mar 6th, 2024 1:40 pm
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
- Mar 3rd, 2024 12:01 pm
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Feb 29th, 2024 9:15 pm
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
- Feb 20th, 2024 1:30 pm
enVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitability
- Jan 6th, 2024 1:29 pm
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
- Dec 14th, 2023 4:30 pm
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
- Nov 16th, 2023 1:45 pm
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Oct 26th, 2023 12:05 pm
enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference
- Oct 12th, 2023 1:00 pm
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
- Oct 6th, 2023 12:57 pm
enVVeno Medical Announces New Expedited Development Plan for the enVVe(R) Transcatheter Based Replacement Venous Valve
- Oct 6th, 2023 12:56 pm
enVVeno Medical Announces Private Placement of $28 Million
- Oct 6th, 2023 12:55 pm
enVVeno Medical Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Jul 31st, 2023 8:45 pm
enVVeno Medical to Host Virtual KOL Event on July 18, 2023
- Jul 14th, 2023 12:05 pm
enVVeno Medical Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study and Announces Upcoming Investor and KOL Events
- Jul 5th, 2023 12:05 pm
Scroll